Driving reinvestment in R&D for antibiotics and advocating their responsible use


DRIVE-AB Members respond to The Lancet Infectious Diseases article on emergence of plasmid-mediated colistin resistance mechanism

Antibiotic Action, the British Society for Antimicrobial Chemotherapy, and the Journal of Antimicrobial Chemotherapy have released an official response to the the The Lancet article titled, “Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study”, published on 18 November 2015 .

Response: Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Yi-Yun Liu et al. Lancet Infectious Diseases November 19 2015

Laura JV Piddock

This is a worrying report as polymyxins are often the last resort antibiotic to treat serious infections by multiple drug-resistant...
Read more

The Lancet Series launched to celebrate Global Antibiotic Awareness Day

In celebration of Global Antibiotic Awareness Day, 18 November 2015, The Lancet, in collaboration with Imperial College London and the Norwegian Institute of Public Health, is publishing a new series titled: “Antimicrobials: sustainable access and effectiveness”. The five papers in the series cover access to effective antimicrobials as a global challenge, understanding the mechanisms and the drivers of antimicrobial resistance, maximising access to achieve appropriate human antimicrobial use in low- and middle-income countries,  exploring the evidence base for national and regional policy interventions to combat resistance, and international cooperation to improve access to and sustain effectiveness of antimicrobials. The launch of the series will...
Read more

UK & China to establish Global Antimicrobial Resistance Research Innovation Fund

During Chinese President Xi Jinping's State Visit to the UK, UK Prime Minister announced a new fund to drive a global response to antimicrobial resistance. The UK and China will establish the Global Antimicrobial resistance Research Innovation Fund and encourage further investment from other governments and the private sector, helping to address one of the greatest problems facing the world of medicine today.   To read more on this story, click here....
Read more

DRIVE-AB participants to present at meeting of the Transatlantic Taskforce on Antimicrobial Resistance

The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) will meet in Luxembourg City, Luxembourg, on 22-23 October 2015 to discuss synergies between Europe and North America in antimicrobial resistance strategies. Major topics will include, among others,  - Action on antimicrobial resistance on both sides of the Atlantic - How do we keep new antibiotics effective? Balancing access and conservation - TATFAR in context: International initiatives on antimicrobial resistance DRIVE-AB participants John-Arne Røttingen (work package 2 co-lead), Ursula Theuretzbacher (work package 3B co-lead), and Otto Cars will be presenting at the meeting. Click here to view...
Read more

DRIVE-AB holds second annual General Assembly

A DRIVE-AB General Assembly was held at Uppsala University in Uppsala, Sweden on 15-16 October 2015. The two-day meeting brought together DRIVE-AB participants from all over the world to discuss DRIVE-AB progress, challenges, and next steps. Each work package presented its progress to date, and opportunities for further collaboration between work packages was explored. In-depth discussions were also held about DRIVE-AB in the context of other global AMR initiatives, stakeholder engagement, how to implement eventual outputs, and the logistics of successfully running a global project. Please click here to view the Agenda: DRIVE-AB General Assembly 2015.     IMG_1582 Read more